We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.00 | -0.67% | 148.918 | 149.89 | 147.82 | 149.89 | 3,177,093 | 18:27:49 |
From May 2019 to May 2024
By Matt Grossman
Johnson & Johnson subsidiary Janssen Pharmaceutical Cos. has filed a new-drug application with the Food and Drug Administration for injections of Uptravi to treat pulmonary arterial hypertension, the company said Wednesday.
Uptravi, a selective prostacyclin IP receptor agonist, was approved in 2015 in oral form to delay the progression of pulmonary arterial hypertension and reduce the risk of hospitalization.
In a new Phase 3 study, in which patients switched between oral and intravenous applications of Uptravi, patients tolerated the switched delivery methods well without unexpected safety findings, Johnson & Johnson said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
September 30, 2020 07:33 ET (11:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
